Abstract: Disclosed are novel compositions and methods for treating systemic lupus erythematosus as well as a model for measuring the efficacy of said treatments.

Abstract: Disclosed are novel compositions and methods for treating systemic lupus erythematosus (SLE) as well as a model for measuring the efficacy of said treatments. Specifically, the disclosure provides a non-human animal model for SLE comprising a severe combined immunodeficient non-human animal comprising exogenous cells from a human subject with SLE, wherein the cells from the human subject are peripheral blood mononuclear cells. Further disclosed is a method of screening for a drug candidate that inhibits or reduces SLE using a severe combined immunodeficient non-human animal.

Abstract: System and methods for automatically scaling compute resources in a compute group. The method includes determining compute capacity required to complete job requests and determining allocable compute capacity available on the compute resources in the compute group. The method further includes calculating a utilization of the compute group based on the required compute capacity and allocable compute capacity and determining whether the calculated utilization is above a first threshold value or below a second threshold value; upon determining that the calculated utilization is above the first threshold value the method calculates a number of compute resources required to bring the utilization below the first threshold value and causes an increase in the number of compute resources in the compute group based on the calculated number. Upon determining that the calculated utilization falls below the second threshold value the method causes a reduction in the number of active compute resources.

Abstract: System and methods for automatically scaling compute resources in a compute group. The method includes determining compute capacity required to complete job requests and determining allocable compute capacity available on the compute resources in the compute group. The method further includes calculating a utilization of the compute group based on the required compute capacity and allocable compute capacity and determining whether the calculated utilization is above a first threshold value or below a second threshold value; upon determining that the calculated utilization is above the first threshold value the method calculates a number of compute resources required to bring the utilization below the first threshold value and causes an increase in the number of compute resources in the compute group based on the calculated number. Upon determining that the calculated utilization falls below the second threshold value the method causes a reduction in the number of active compute resources.

Abstract: System and methods for automatically scaling compute resources in a compute group. The method includes determining compute capacity required to complete job requests and determining allocable compute capacity available on the compute resources in the compute group. The method further includes calculating a utilization of the compute group based on the required compute capacity and allocable compute capacity and determining whether the calculated utilization is above a first threshold value or below a second threshold value; upon determining that the calculated utilization is above the first threshold value the method calculates a number of compute resources required to bring the utilization below the first threshold value and causes an increase in the number of compute resources in the compute group based on the calculated number. Upon determining that the calculated utilization falls below the second threshold value the method causes a reduction in the number of active compute resources.

Abstract: A polymer film assembly includes a stack of two or more polymer films. At least one of the polymer films includes directionally oriented molecules. The stack includes a first polymer film and a second polymer film layered with the first polymer film. A contracted bond assembly couples the first and second polymer films of the stack. The contracted bond assembly includes heated and contracted configurations. In the heated configuration the contracted bond assembly includes a bond fusion zone and a film interface having directionally disoriented molecules and an interface width between the bond fusion zone and the remainder of the first and second polymer films. In the contracted configuration the film interface is a contracted film interface having a contracted interface width less than the interface width and a contracted thickness greater than one or more of film thicknesses of the first or second polymer films.

Abstract: System and methods for automatically scaling compute resources in a compute group. The method includes determining compute capacity required to complete job requests and determining allocable compute capacity available on the compute resources in the compute group. The method further includes calculating a utilization of the compute group based on the required compute capacity and allocable compute capacity and determining whether the calculated utilization is above a first threshold value or below a second threshold value; upon determining that the calculated utilization is above the first threshold value the method calculates a number of compute resources required to bring the utilization below the first threshold value and causes an increase in the number of compute resources in the compute group based on the calculated number. Upon determining that the calculated utilization falls below the second threshold value the method causes a reduction in the number of active compute resources.

Abstract: Disclosed are novel compositions and methods for treating systemic lupus erythematosus (SLE) as well as a model for measuring the efficacy of said treatments. Specifically, the disclosure provides a non-human animal model for SLE comprising a severe combined immunodeficient non-human animal comprising exogenous cells from a human subject with SLE, wherein the cells from the human subject are peripheral blood mononuclear cells. Further disclosed is a method of screening for a drug candidate that inhibits or reduces SLE using a severe combined immunodeficient non-human animal.